Menu
  • Join
  • Login
  • Contact
 

Search abstracts


THE VALSARTAN SAGA: SCIENCE, MYTHS AND REALTIES

  • At: 2019 FIP Congress in AbuDhabi (United Arab Emirates)
  • Type: Poster
  • By: BALDACCHINO, Stephania (University of Malta, Pharmacy Department, Malta)
  • Co-author(s): Stephania Baldacchino: Pharmacy Department, University of Malta, Msida, Malta
    Anthony Serracino-Inglott: Malta Medicines Authority , Malta Medicines Authority, San Gwann, Malta;Pharmacy Department, University of Malta, Msida, Malta
    Annalise Attard: Malta Medicines Authority, Malta Medicines Authority, San Gwann, Malta
    Caroline Muscat: Malta Medicines Authority, Malta Medicines Authority, San Gwann, Malta
  • Abstract:

    Background

    Detection of N-nitrosodimethylamine (NDMA), a potential human carcinogen in the manufacture of the valsartan active pharmaceutical ingredient, led to the withdrawal of several contaminated valsartan medicinal products. 

    Methods

    Part I involved an in-depth analysis of the significance of the NDMA impurity in valsartan medicines through a

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 21 September 2019

FIP Congresses